Pharmaceutical - Anti-virals, Research

Filter

Current filters:

Anti-viralsResearch

Popular Filters

1 to 25 of 95 results

Boehringer Ingelheim pulls out of hepatitis C drug development

Boehringer Ingelheim pulls out of hepatitis C drug development

23-06-2014

German family-owned pharma major Boehringer Ingelheim revealed that, following a re-evaluation of its…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

11-06-2014

Privately-held California, USA-based specialty vaccine firm PaxVax has entered into a research and development…

Anti-viralsLicensingPaxVaxPharmaceuticalResearchVaccines

Janssen expands accord with IPM for dapivirine in prevention of sexual transmission of HIV

08-05-2014

Janssen R&D Ireland, a unit of US health care giant Johnson & Johnson, has expanded its collaboration…

Anti-viralsJanssenJohnson & JohnsonPharmaceuticalResearch

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

10-04-2014

US pharma major Bristol-Myers Squibb has presented new Phase III trial data of its combination therapy…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Promising results for Merck & Co’s hepatitis C drug combo

Promising results for Merck & Co’s hepatitis C drug combo

10-04-2014

US pharma giant Merck & Co has announced additional data from the ongoing C-WORTHy study, a multi-arm…

Anti-viralsMerck & CoMK-5172PharmaceuticalResearch

Positive new Ph III data from once-daily simeprevir presented at APASL

18-03-2014

Encouraging new Phase III data for the once-daily protease inhibitor simeprevir (trade name Olysio in…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalResearchsimeprevir

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

07-03-2014

USA pharma giant Merck & Co subsidiary MSD says that in a 96-week, open-label AIDS Clinical Trials Group…

Anti-viralsIsentressMerck & CoPharmaceuticalResearch

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

06-03-2014

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

03-02-2014

Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today.

Anti-viralsAtriplaInterviewsIsentressPharmaceuticalPrezistaRegulationResearchTivicayUKViiV Healthcare

Janssen sets up new group targeting unmet global health needs

Janssen sets up new group targeting unmet global health needs

22-01-2014

US health care giant Johnson & Johnson’s Janssen companies are forming Janssen Global Public Health,…

Anti-viralsAntibiotics and Infectious diseasesJanssenJohnson & JohnsonPharmaceuticalResearch

ViiV Healthcare’s new HIV medicine Tivicay is approved in Europe

21-01-2014

The European Commission has approved Tivicay (dolutegravir) made by Viiv Healthcare for use in combination…

Anti-viralsEuropePharmaceuticalResearchTivicayViiV Healthcare

BiondVax’ universal flu vaccine matches all six potentially pandemic flu strains in the world

21-01-2014

BiondVax Pharmaceuticals, an Israeli company developing a universal flu vaccine, says it has completed…

Anti-viralsBiondVaxPharmaceuticalResearchVaccines

New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

16-01-2014

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans…

Anti-viralsBristol-Myers SquibbdaclatasvirGilead SciencesPharmaceuticalResearchsofosbuvir

UK MPs express concerns on clinical trial data transparency and Tamiflu stockpiling

UK MPs express concerns on clinical trial data transparency and Tamiflu stockpiling

06-01-2014

The UK House of Commons Public Accounts Committee is calling for all data on drugs being prescribed in…

Anti-viralsNorthern EuropePharmaceuticalRegulationResearchRocheTamifluUK

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

17-12-2013

New data show that family-owned German drug major Boehringer Ingelheim’s second-generation protease…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalResearch

AbbVie reports 96% response in Phase III hepatitis C study

AbbVie reports 96% response in Phase III hepatitis C study

10-12-2013

US drugmaker AbbVie (NYSE: ABBV)has released Phase III results for the investigational three direct-acting-antiviral…

AbbVieAnti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

Teva unveils new pipeline assets from its 2013 NTE program

Teva unveils new pipeline assets from its 2013 NTE program

05-12-2013

Best known as the world’s biggest generic drugmaker, Israel’s Teva Pharmaceutical Industries yesterday…

Anti-viralsCopaxoneNeurologicalPharmaceuticalResearchTeva Pharmaceutical Industries

Bristol-Myers Squibb refocuses R&D strategy

Bristol-Myers Squibb refocuses R&D strategy

08-11-2013

US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued…

Anti-viralsBristol-Myers SquibbDiabetesManagementNeurologicalOncologyPharmaceuticalResearch

First ever flu vaccine developed by Chinese researchers

28-10-2013

Chinese researchers have successfully developed the vaccine for the H7N9 bird flu virus, after the flu…

Anti-viralsAsia-PacificPharmaceuticalResearchTianyuan Bio-Pharmaceutical

1 to 25 of 95 results

Back to top